Mesenteric venous thrombosis attributed to docetaxel

被引：8

作者：

Feenstra, J

Vermeer, RJI

Stricker, BHC

机构：

[1] Erasmus Univ, Sch Med, Dept Epidemiol & Biostat, Pharmacoepidemiol Unit, NL-3000 DR Rotterdam, Netherlands

[2] Erasmus Univ, Sch Med, Dept Internal Med, Pharmacoepidemiol Unit, NL-3000 DR Rotterdam, Netherlands

[3] Inspectorate Hlth Care, Drug Safety Unit, The Hague, Netherlands

[4] Hosp Tjongerschans, Dept Internal Med, Heerenveen, Netherlands

来源：

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 2000年 / 23卷 / 04期

关键词：

mesenteric venous thrombosis; docetaxel;

D O I：

10.1097/00000421-200008000-00008

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We present a case of a 57-year-old woman with metastatic breast cancer unresponsive to several chemotherapeutic and hormonal regimens. Because of progressive pulmonary metastases and a painful osteolytic metastasis in the sternum, treatment with docetaxel was initiated. She developed mesenteric venous thrombosis within 1 week after the first dose of docetaxel. Although docetaxel may be regarded as an important advancement in the chemotherapeutic treatment of several cancers, ongoing and future trials must assess its position in the standard chemotherapeutic treatment of cancer. Well-documented adverse reactions, either common or rare, may contribute to a balanced risk-benefit profile of docetaxel.

引用

页码：353 / 354

页数：2